

Molecular Mechanism Underlying Phosphatidylinositol 4,5-Bisphosphate-induced Inhibition of SpIH Channels*

Received for publication, December 20, 2010, and in revised form, February 15, 2011 Published, JBC Papers in Press, March 7, 2011, DOI 10.1074/jbc.M110.214650

Galen E. Flynn and William N. Zagotta¹

From the Department of Physiology and Biophysics, Howard Hughes Medical Institute, University of Washington, Seattle, Washington 98195-7290

Many ion channels have been shown to be regulated by the membrane signaling phospholipid phosphatidylinositol 4,5-bisphosphate (PIP₂). Here, we demonstrate that the binding of PIP₂ to SpIH, a sea urchin hyperpolarization-activated cyclic nucleotide-gated ion channel (HCN), has a dual effect: potentiation and inhibition. The potentiation is observed as a shift in the voltage dependence of activation to more depolarized voltages. The inhibition is observed as a reduction in the currents elicited by the partial agonist cGMP. These two effects were separable and arose from PIP₂ binding to two different regions. Deletion of the C-terminal region of SpIH removed PIP₂-induced inhibition but not the PIP₂-induced shift in voltage dependence. Mutating key positively charged amino acids in the C-terminal region adjacent to the membrane selectively disrupted PIP₂-induced inhibition, suggesting a direct interaction between PIP₂ in the membrane and amino acids in the C-terminal region that stabilizes the closed state relative to the open state in HCN channels.

HCN channels are integral membrane proteins that are activated by membrane hyperpolarization and modulated by the direct binding of intracellular cyclic nucleotides. These channels underlie the *I_f* current in cardiac cells, where they tune pacemaker activity, and the *I_h* current in neuronal cells, where they act to oppose deviations away from the resting membrane potential, thereby stabilizing cellular excitability (1–8). There are four mammalian isoforms, HCN1–HCN4 (9–11). They are members of the voltage-activated family of ion channel proteins. Like other members of this family, HCN channels are tetramers of similar or identical subunits that surround a central ion-conducting pore through the membrane. Each subunit is composed of a cytoplasmic N- and C-terminal region and a core region formed by the six transmembrane helices S1–S6. A single transmembrane pore is formed by the S5–S6 segments contributed by each of the four subunits, whereas the four voltage-sensing domains are formed by the S1–S4 segments from individual subunits (1–8, 12, 13).

The cytoplasmic C-terminal region contains a cyclic nucleotide-binding domain (CNBD)² and a C-linker domain that connects the CNBD to the pore. In most mammalian HCN channels, binding of cAMP to the CNBD results in a depolarizing shift in the voltage dependence of activation, causing these channels to open more easily at resting membrane potentials (14, 15). However, in the HCN channel from sea urchin (SpIH), binding of cAMP does not shift the voltage dependence but causes a large increase in the current due to the removal of autoinhibition (4). The atomic structures of the C-terminal region of both HCN2 and SpIH bound to cAMP have been resolved by x-ray crystallography (Fig. 1) (15, 16). In each case, the C-terminal fragments assemble as 4-fold symmetric tetramers. The C-linker regions of each subunit form a gating ring predicted to be adjacent to the cytoplasmic surface of the membrane (Fig. 1A). Attached to each C-linker is the CNBD (Fig. 1B). The CNBD of HCN channels shares substantial sequence and structural similarity with the CNBD of other cyclic nucleotide-binding proteins such as cAMP-dependent protein kinase and catabolite gene activator protein (15, 17, 18). Interestingly, despite the functional differences between SpIH and HCN2, their structures are very similar (root mean square deviation of the C α atoms of 0.86 Å) (15, 16).

Recently, acidic phospholipids were shown to regulate HCN channel activation. Direct application of either exogenous phosphatidylinositol 4,5-bisphosphate (PIP₂) or its soluble form, dioctanoyl (diC₈)-PIP₂, to excised inside-out patches containing HCN channels causes a depolarizing shift in the voltage dependence of activation (19, 20). The PIP₂-induced shift occurs in all mammalian HCN channels tested thus far (HCN1, HCN2, and HCN4). In addition, PIP₂ also shifts the activation voltage of HCN2_{ΔCNBD} channels, in which the CNBD was deleted, suggesting that the mechanism for the voltage-dependent shift by PIP₂ is distinct from the mechanism for the voltage-dependent shift by cAMP (19).

Here, we show that, in addition to shifting the voltage dependence of activation, PIP₂ also inhibits SpIH channels. Our results suggest that PIP₂ binds to two separate regions: 1) the transmembrane core region, which produces potentiation, and 2) the C-linker domain, which produces inhibition. Two basic residues in the C-linker domain near the membrane were found to be involved in the inhibition of the channel by PIP₂. These results suggest a model in which membrane-incorporated PIP₂

* This work was supported, in whole or in part, by National Institutes of Health Grant EY10329 from NEI (to W. N. Z.). This work was also supported by the Howard Hughes Medical Institute.

⌘ Author's Choice—Final version full access.

¹ To whom correspondence should be addressed: Dept. of Physiology and Biophysics, P.O. Box 357290, University of Washington, Seattle, WA 98195-7290. Tel.: 206-685-3878; Fax: 206-543-0934; E-mail: zagotta@u.washington.edu.

² The abbreviations used are: CNBD, cyclic nucleotide-binding domain; PIP₂, phosphatidylinositol 4,5-bisphosphate; diC₈, dioctanoyl; PIP, phosphatidylinositol 4-monophosphate; CNG, cyclic nucleotide-gated.




FIGURE 1. **Summary of the structure of a SpIH C-terminal fragment.** *A*, side view showing the SpIH C-terminal structure (amino acids 470–665). Three subunits are shown in a surface representation, and one subunit is in ribbon representation. The tetrameric structure is positioned beneath a schematic diagram representing the transmembrane domain idealized from the space-filled model of Kv1.2 (32). *B*, ribbon representation of a single SpIH C-terminal structure (Protein Data Bank code 2PTM). Helices are colored red (A'–F', A–C, and P), β -sheets are colored cyan, and connecting loops are colored black.

binds to the C-linker and stabilizes the closed state of the HCN channel.

EXPERIMENTAL PROCEDURES

DNA Preparation for Physiology—SpIH cDNA (a gift from U. B. Kaupp) was subcloned into the pGEMHE high expression vector (a gift from E. Liman), where it was flanked by the *Xenopus* β -globin gene 5' and 3' UTRs. All cDNAs were linearized by digestion with SphI and then transcribed *in vitro* using the Ambion T7 mMESSAGE mMACHINE into mRNAs. The mRNA was injected into surgically isolated stage IV *Xenopus* oocytes as described previously (21). All mutations were generated using oligonucleotide-directed PCR mutagenesis and confirmed with fluorescence-based DNA sequencing.

Electrophysiology—Electrophysiology experiments were conducted on full-length and truncated SpIH or SpIH mutant channels exogenously expressed in plasma membranes of *Xenopus* oocytes. SpIH currents were recorded from excised inside-out macropatches using conventional patch-clamp recording techniques (22). Both pipette and bath solutions contained 130 mM KCl, 0.2 mM EDTA, and 3 mM HEPES (pH 7.2). To modulate SpIH and mutant channels, saturating concentrations of cyclic nucleotides (1 mM cGMP or cAMP) were applied in the absence or presence of 10–30 μ M PIP₂ using a rapid solution changer (RSC-100, Bio-Logic). Ionic currents were amplified and low pass-filtered at 2 kHz using an Axopatch 200A system (Axon Instruments, Inc.). The currents were digitized at 10 kHz using an ITC-16 DA/AD converter (Instrutech Corp.) interfaced to a computer running PULSE software (HEKA Electronics, Inc.) and stored in files for offline analysis using IGOR software (WaveMetrics) or Excel software (Microsoft).

diC₈-PIP₂ and diC₈-phosphatidylinositol-4-monophosphate (PIP) were purchased from Avanti Polar Lipids and stored at –20 °C until needed. On the day of the experiment, 1.5 mM stock solutions were made by adding water to the newly opened vial unless we were studying dose-response relationships. In that case, we added 1 mM cGMP in recording buffer instead of water. The solution was then kept on ice. Just prior to the appli-

cation to the patch, the PIP₂ was diluted with 1 mM cGMP to 10 or 30 μ M generally in a volume of 2 ml. The solution was applied to the cytoplasmic side of inside-out patches within 3 min using a gravity-controlled perfusion system (RSC-100). Currents in response to voltages from –20 to –120 mV were continuously measured during the application of PIP₂ for 10 min or until we lost the patch.

Data Analysis—To determine the voltage dependence and shifts in voltage dependence due to PIP₂ modulation, we calculated the conductance-voltage (*G*-*V*) relationship for wild-type and mutant channels in the absence and presence of cyclic nucleotides and cyclic nucleotides + PIP₂. Peak tail current amplitudes were measured at –40 mV after being presented with an activating test pulse voltage given in the range of –20 to –130 mV. Currents were plotted against the test voltages (*G*-*V* plot), and the data were fit with the Boltzmann equation: $G = \text{base} + G_{\text{max,cNMP}} / (1 + e^{(-z\delta(V - V_{1/2})/RT)})$, where base is the non-voltage-dependent leak conductance, *V* is the test pulse voltage, *V*_{1/2} is the activation midpoint voltage, and *z* δ is the equivalent charge movement. We corrected for leak conductance by subtracting the non-voltage-dependent conductance (base) determined from the Boltzmann fit. The currents were normalized to the *G*_{max,cAMP} determined at saturating voltages, –120 mV or greater. All fitting was performed with IGOR software.

To calculate the energetic effects on SpIH channel opening caused by PIP₂ modulation ($\Delta\Delta G$), we assumed that our mutations outside the cyclic nucleotide-binding site did not change the cyclic nucleotide specificity of the channel. Therefore, the ratio of the opening equilibrium constants for cAMP and cGMP will be constant for all wild-type and mutant channels. Using the published values for wild-type SpIH channel open probability in cAMP (*P*_{o,cAMP} = 0.91) and cGMP (*P*_{o,cGMP} = 0.54) (16), we calculated the opening equilibrium constants (*L*_{cAMP} and *L*_{cGMP}) for wild-type SpIH channels: $L_{\text{cGMP}} = P_{\text{o,cGMP}} / (1 - P_{\text{o,cGMP}})$ and $L_{\text{cAMP}} = P_{\text{o,cAMP}} / (1 - P_{\text{o,cAMP}})$. Using these *L* values, we calculated the maximum conductance (*G*_{max}) from *G*_{cAMP} and *G*_{cGMP} measured in each experiment

using the following equation: $G_{\max} = ((L_{cGMP}/L_{cAMP}) - 1)/(((L_{cGMP}/L_{cAMP})/G_{cGMP}) - (1/G_{cAMP}))$. With G_{\max} , we determined the energetics of channel opening using $\Delta G = -RT \ln((G/G_{\max})/(1 - (G/G_{\max})))$, where G represents the conductance determined for cAMP, cGMP, or cGMP + PIP₂ at saturating negative voltages; R is the ideal gas constant; and T is the absolute temperature. We also calculated the difference in opening free energy change resulting from PIP₂ binding using the following equation: $\Delta\Delta G = \Delta G_{cGMP,PIP_2} - \Delta G_{cGMP}$.

Data for PIP₂ and PIP dose-response relationships were taken from current measurements at saturating negative test voltages to -120 mV and normalized to $I_{\max, No PIP}$. Current amplitudes were plotted against applied PIP₂ or PIP concentration, and data were fit with the Hill equation: $I = (I_{\text{base}}/(I_{\max, No PIP_2} - I_{\text{base}}))/(1 + (K_{1/2}/[PIP_2])^h)$, where $[PIP_2]$ is the phospholipid concentration, $K_{1/2}$ is the agonist concentration eliciting half-maximal response, and h is the Hill coefficient.

Data parameters were expressed as means \pm S.E. and tabulated for comparison. One-way analysis of variance was performed using the Microsoft Excel statistical function with a significance level of 0.05. A post hoc Student's t test was used to determine which of the mutants was statistically different at $p < 0.05$.

RESULTS

Cyclic Nucleotide Regulation of SpIH—HCN channels open their transmembrane pore in response to both membrane hyperpolarization and the direct binding of cyclic nucleotides to a specialized C-terminal domain (1, 2). SpIH is an HCN channel from sea urchin that exhibits properties somewhat different from those of mammalian HCN channels (4). In the absence of cyclic nucleotides, SpIH currents recorded from inside-out macropatches of *Xenopus* oocytes were very small and rapidly inactivated in response to membrane hyperpolarization (Fig. 2A, black traces). After intracellular cAMP was applied, there was a large increase in current associated with a removal of autoinhibition (Fig. 2A, red trace) (23, 24). Unlike for mammalian HCN channels, cAMP causes little or no shift in the voltage dependence of SpIH (4). Interestingly, truncated SpIH channels lacking a C-terminal region (SpIH_{ΔC}) produced large non-inactivating currents that were insensitive to cAMP (Fig. 2B) (13, 24). The response of SpIH_{ΔC} channels to membrane hyperpolarization was similar to that of wild-type SpIH channels bound to cAMP. These and similar results in mammalian HCN channels led to the conclusion that, in HCN channels, the C-terminal domain acts as an autoinhibitory domain and that the binding of cyclic nucleotides releases this inhibition, facilitating channel opening (24).

SpIH channels also differ from other HCN channels in agonist specificity (4). As shown in Fig. 2, application of 1 mM cAMP to SpIH channels caused a dramatic increase in the current over control currents in the absence of cyclic nucleotide (Fig. 3, A and B, dashed red versus dashed black traces). Unlike for other HCN channels, however, cGMP behaved as a partial agonist of SpIH channels (Fig. 3, A and B, dashed green versus dashed red traces). At hyperpolarized voltages, saturating concentrations of cGMP activated only about half the amount of current activated by cAMP (16). The difference in the amount




FIGURE 2. The C terminus acts as an autoinhibitory domain. A, schematic of the membrane topology of a single subunit of the SpIH channel. Representative currents were measured from inside-out excised patches of oocyte membrane. Voltage pulses were applied to patches in the range of -30 to -120 mV, followed by a voltage step to -40 mV. The holding voltage was 0 mV. Currents were measured in the absence of cyclic nucleotides (black traces) and in the presence of 1 mM cAMP (red traces). B, schematic representing the topology of the C-terminal deletion mutant (deleted amino acids 471–767). Representative currents were measured over a voltage range of -40 to -120 mV from a 0-mV holding potential in the absence of cyclic nucleotides.

of current elicited by saturating cGMP and cAMP reflects a difference in efficacy between the two ligands to stabilize the open state of the channel relative to the closed state and not a difference in single-channel conductance (16). These results indicate that, in SpIH channels, cGMP only partially stabilizes channel opening, whereas cAMP produces a greater stabilization. Therefore, the partial activation by cGMP can be used as a sensitive reporter of the energetics of agonist activation of SpIH channels.

PIP₂ Regulation of SpIH—Earlier studies have shown that PIP₂ acts as an allosteric modulator of mammalian HCN channels. Depletion of endogenous PIP₂ from the membrane causes a negative shift in voltage dependence upon patch excision (19, 20). Additionally, when exogenous PIP₂ or the soluble form, diC₈-PIP₂, is applied to HCN channels in inside-out patches, a positive shift in voltage dependence of activation occurs (19). We used the voltage dependence and cyclic nucleotide dependence of gating in SpIH channels to study the molecular mechanism of phosphoinositide modulation using soluble diC₈-PIP₂ (hereafter referred to as PIP₂). We found that, as in mammalian HCN channels, PIP₂ modulated SpIH channels (Fig. 3A, solid traces). After an initial 20-min waiting period for the depletion of endogenous PIP₂, we applied 10 μ M PIP₂ to SpIH channels in inside-out patches, which caused a positive shift in the voltage dependence of activation in the presence of either cAMP or cGMP (Fig. 3B, solid traces). PIP₂ shifted the midpoint of the activation ($\Delta V_{1/2}$) ~ 10 mV toward depolarizing voltages for both cAMP and cGMP (Fig. 3C).

Interestingly, however, in SpIH, PIP₂ also produced a significant inhibition of the currents measured at hyperpolarized voltages and saturating cGMP concentrations (Fig. 3A). In the absence of PIP₂, the maximum conductance of cGMP-modu-

PIP₂ Inhibits SpIH




FIGURE 3. Effects of PIP₂ on cyclic nucleotide-modulated SpIH channels. *A*, representative currents measured in response to a hyperpolarizing voltage step to -120 mV, followed by a voltage step to -40 mV from a holding voltage of 0 mV. Currents were measured in the absence of cyclic nucleotide (*dashed black trace*) and in the presence of 1 mM cGMP (*dashed green trace*), 1 mM cAMP (*dashed red trace*), cAMP + $10 \mu\text{M}$ diC₈-PIP₂ (*solid red trace*), and cGMP + $10 \mu\text{M}$ diC₈-PIP₂ (*solid green trace*). *B*, normalized G - V relationships for each condition in *A*. Tail currents at -40 mV were measured and normalized to the tail currents measured in the presence of 1 mM cAMP (*dashed red trace* in *A*). *Solid* and *dotted curves* represent fits to the data of the Boltzmann equation (see "Experimental Procedures"). Leak currents were subtracted as described under "Experimental Procedures." *C*, bar graph showing the mean \pm S.E. of the PIP₂-induced shift in the midpoint of the voltage dependence ($\Delta V_{1/2} = V_{1/2, \text{PIP}_2} - V_{1/2}$) for both cAMP- and cGMP-modulated channels ($n = 5$). *D*, bar graph showing the mean \pm S.E. of the relative normalized conductance ($G/G_{\text{max,cAMP}}$) for cyclic nucleotide-modulated channels in the absence and presence of PIP₂ ($n = 5$). cA, cAMP; cG, cGMP.

lated channels was about half the conductance of cAMP-modulated channels ($G_{\text{cGMP}}/G_{\text{max,cAMP}} = 0.57 \pm 0.04$, $n = 5$) (Fig. 3*B*, *dotted green curve*). Assuming a simple closed-open equilibrium, this fractional activation by cGMP corresponds to a free energy change (ΔG) for opening in cGMP of -0.11 ± 0.09 kcal/mol ($n = 5$) (see "Experimental Procedures"). After 10 min in the presence of $10 \mu\text{M}$ PIP₂, the cGMP-induced current at hyperpolarized voltages was inhibited by $\sim 50\%$ ($G_{\text{cGMP,PIP}_2}/G_{\text{max,cAMP}} = 0.28 \pm 0.03$, $n = 5$) (Fig. 3*B*, *solid green curve*); or $\Delta G = 0.61 \pm 0.08$ kcal/mol (Fig. 3*D*). This suggests that PIP₂ caused a change in the free energy of opening in the presence of cyclic nucleotides ($\Delta\Delta G$) of $\sim 0.72 \pm 0.02$ kcal/mol ($n = 5$). As expected for a change in free energy, currents measured in the more efficacious agonist cAMP exhibited a much smaller decrease in $10 \mu\text{M}$ PIP₂ ($G_{\text{cAMP,PIP}_2}/G_{\text{max,cAMP}} = 0.93 \pm 0.02$, $n = 5$) (Fig. 3*D*). The inhibition seen at large negative voltages at saturating cyclic nucleotide concentrations suggests that PIP₂ is stabilizing the closed state of channels relative to the open state.

Localization of PIP₂ Effects—We observed that PIP₂ produced two effects on SpIH channels: potentiation of the voltage-dependent gating and inhibition of the cyclic nucleotide-dependent gating. To identify regions involved in PIP₂ regulation, we applied PIP₂ to SpIH _{Δ C} channels. As shown previously, currents measured from channels lacking a C-terminal region were large and similar in time course to currents measured in the presence of cAMP (Fig. 4*A*). We found that $30 \mu\text{M}$ PIP₂ produced a depolarizing shift in the voltage dependence

that changed the half-maximal activating voltage ($\Delta V_{1/2}$) by 4.8 ± 0.9 mV ($n = 3$) (Fig. 4, *B*, *C*, and *G*). This voltage shift for SpIH _{Δ C} was similar although somewhat smaller than what we observed in wild-type SpIH channels bound by cAMP or cGMP. In contrast to wild-type channels, however, PIP₂ did not inhibit SpIH _{Δ C}. On the contrary, SpIH _{Δ C} exhibited a small reversible potentiation in the maximum conductance ($G_{\text{PIP}_2}/G_{\text{max,No PIP}_2} = 1.13 \pm 0.06$, $n = 3$) (Fig. 4, *C* and *H*), unlike cAMP-modulated wild-type SpIH channels (Fig. 3). Similarly, SpIH channels lacking both N- and C-terminal regions (SpIH _{Δ NC}) also showed a depolarizing shift in voltage dependence ($\Delta V_{1/2} = 7.8 \pm 0.98$ mV, $n = 4$) and a small reversible increase in maximum conductance ($G_{\text{PIP}_2}/G_{\text{max,No PIP}_2} = 1.09 \pm 0.24$, $n = 4$) (Fig. 4, *E*–*H*). These results show that the potentiating effects of PIP₂ on voltage-dependent gating can be physically separated from the inhibitory effects of PIP₂ on ligand gating. The reversible increase in maximum conductance observed in the deletion mutants is a further indication that the potentiating effect induced by PIP₂ is distinct from the inhibitory effect, which accounts for the lack of an increase in conductance in wild-type SpIH in the presence of cAMP. From these results, we conclude that PIP₂ interacts with two distinct sites on the channel: one site in the transmembrane region (amino acids 161–470) that shifts the voltage dependence and a second site in the intracellular C-terminal region (deleted amino acids 471–767) that inhibits the cyclic nucleotide regulation.




FIGURE 4. The C-terminal domain mediates PIP₂ inhibition and the transmembrane domain mediates PIP₂-induced positive shift in voltage. *A* and *B*, representative currents recorded from SpIH_{ΔC} channels lacking the C-terminal region (deleted amino acids 471–767) in response to voltage steps between –40 and –130 mV in the absence and presence of 30 μM diC₈-PIP₂. The red trace indicates currents measured at the same voltage, –70 mV. *C*, *G*-*V* relationships for SpIH_{ΔC} measured from tail currents at –40 mV in the absence of PIP₂ (black circles), in the presence of 30 μM diC₈-PIP₂ (gray circles), and after PIP₂ was washed out (white circles). The curves represent fits of the Boltzmann equation to the data. *D* and *E*, representative currents recorded from C-terminal deleted SpIH_{ΔNC} channels (deleted amino acids 1–160 and 471–767) in response to voltage steps between –40 and –130 mV in the absence and presence of 30 μM diC₈-PIP₂. The red trace indicates currents measured at the same voltage, –90 mV. *F*, *G*-*V* relationships for SpIH_{ΔNC} measured from tail currents at –90 mV in the absence of PIP₂ (black circles), in the presence of 30 μM diC₈-PIP₂ (gray circles), and after PIP₂ was washed out (white circles). *G*, change in voltage dependence as determined for the difference in *V*_{1/2} before and after modulation by PIP₂ ($\Delta V_{1/2}$). *H*, normalized conductance in diC₈-PIP₂ for SpIH_{ΔC} and SpIH_{ΔNC}.

Identification of the PIP₂ Site for Inhibition of Cyclic Nucleotide-dependent Gating—The acyl chains of PIP₂ are expected to intercalate into the hydrophobic regions of the plasma membrane, whereas the negatively charged headgroup extends into the cytoplasm. Given this physical arrangement of these molecules, the negative charges on PIP₂ most likely interact with positively charged residues in the region of the HCN channel protein adjacent to the membrane. The atomic structure of the C-terminal region of SpIH was resolved by x-ray crystallography (Fig. 1) (16). The C-terminal region contains a C-linker domain followed by a CNBD. The C-linker domain begins immediately after the pore-lining S6 transmembrane helix and contains six α -helices (A'–F'). It is the site of virtually all of the intersubunit interactions in the C-terminal region, primarily interactions between the A' and B' helices of one subunit and the C' and D' helices of a neighboring subunit. The A' helix is predicted to lie adjacent to and nearly parallel to the plasma membrane. The amino acid sequence of the A' helix contains four positively charged residues, Arg-475, Arg-478, Lys-480, and Lys-482 (Fig. 5A). With the exception of Lys-480, all of these residues are on the same surface of the A' helix, and they all point toward the membrane (Fig. 5B). Lys-480 points away from the plasma membrane and interacts with the C' helix of the neighboring subunit through a salt bridge with Glu-522.

Arg-475, Arg-478, and Lys-482 are positioned to interact with PIP₂ in the inner leaflet of the membrane.

We hypothesized that the positively charged amino acids of the A' helix are involved in electrostatic interactions with PIP₂ in the plasma membrane and that these interactions are responsible for the PIP₂-induced inhibition of SpIH. To test our hypothesis, we mutated each of the three residues individually and quantified the inhibitory effects elicited by PIP₂. In each case, a positively charged amino acid was replaced with cysteine. To ensure that our mutant channels were free of endogenous PIP₂, we waited 20 min after patch excision for the depletion of endogenous PIP₂ before applying exogenous PIP₂. We started by characterizing each mutant channel over a range of test voltages, –20 to –120 mV, in the absence of cyclic nucleotides, in 1 mM cGMP, and in 1 mM cAMP (Fig. 6). Two of the mutant channels, R475C and R478C, exhibited increases in the fractional activation by cGMP ($G_{cGMP}/G_{max,cAMP}$) at hyperpolarized voltages relative to wild-type SpIH (Fig. 6, A–D). In addition, R475C exhibited an increase in fractional activation in the absence of cyclic nucleotide, suggesting that the CNBD does not autoinhibit R475C mutant channels as efficiently as wild-type channels. The voltage dependence of activation for all three mutants was very close to that for wild-type SpIH.

PIP₂ Inhibits SpIH




FIGURE 5. Positively charged residues in the A' helix of SpIH near the membrane. *A*, sequence alignment of amino acids in the A' helix of SpIH and related CNG channels. *Red arrows* indicate the positions of positively charged residues in SpIH. *B*, model of the atomic structure of SpIH showing positive residues in the A' helix as *sticks* on the ribbon backbone (Lys-475, Arg-478, and Lys-482; *red*). Lys-480 (*blue sticks*) points away from the membrane and forms an intersubunit salt bridge (*dashed red line*) with Glu-522 in the neighboring subunit (*yellow stick in the yellow subunit*). The position of the membrane is shown by the *labeled bar*.

Next, we evaluated the functional effects of PIP₂ on each of the three mutant channels. All three mutant channels exhibited depolarizing shifts in voltage in response to 10 μ M PIP₂ (Fig. 6, *B*, *D*, and *F*). Although R475C exhibited PIP₂-induced reduction in cGMP-activated current, both R478C and K482C exhibited significantly less inhibition by PIP₂. The amount of PIP₂ inhibition observed depended on the free energy of opening, and for the R475C mutant, the opening in cGMP is more favorable than for the wild type (cGMP is almost a full agonist), so the inhibition appeared less (Fig. 7). Our thermodynamic analysis took this into account (see calculation of ΔG under "Experimental Procedures"). The $\Delta\Delta G$ for PIP₂-induced inhibition of K478C was significantly different from that in the wild type (one-way analysis of variance and post hoc Student's *t* test, $p < 0.01$). These results suggest that Arg-478 and Lys-482 can interact with PIP₂ in the membrane and stabilize the closed state relative to the open state.

Finally, we determined the apparent affinity of PIP₂ and diC₈-PIP for producing inhibition in both wild-type SpIH and the K478C mutant. Currents were recorded in the presence of 1 mM cGMP and varying concentrations of PIP₂ for wild-type SpIH or K478C (Fig. 8, *A* and *B*). The amplitudes of currents elicited by -120 -mV test pulses were measured and plotted relative to the PIP₂ concentration (Fig. 8*C*). We averaged the dose-response data from three patches and fit these data with the Hill equation (see "Experimental Procedures"). The fit to the dose-response data for SpIH yielded a maximum inhibition by PIP₂ of $I_{\text{PIP}_2}/I_{\text{cGMP, No PIP}_2} = 55\%$, $K_{1/2} = 3.6 \mu\text{M}$, and Hill coefficient = 1 (Fig. 8*C*, *closed circles*). The maximum inhibition of wild-type SpIH by PIP was $I_{\text{PIP}}/I_{\text{cGMP, No PIP}} = 49\%$, $K_{1/2} = 13.6 \mu\text{M}$, and Hill coefficient = 1 (Fig. 8*D*, *open circles*). In contrast, the dose-response relationships of R478C for both PIP₂ and PIP were nearly flat with respect to the concentration of phosphoinositides (Fig. 8, *C* and *D*, *squares*). These results show that both PIP₂ and PIP inhibit SpIH similarly but with




FIGURE 6. Effects of 10 μ M PIP₂ on cyclic nucleotide modulation of mutant SpIH channels (R475C, R478C, and K482C). *A*, *C*, and *E*, representative currents measured in response to a hyperpolarizing voltage step to -120 mV, followed by a voltage step to -40 mV from a holding voltage of 0 mV. Currents were measured in the absence of cyclic nucleotide (*dashed black trace*) and in the presence of 1 mM cGMP (*dashed green trace*), 1 mM cAMP (*dashed red trace*), cAMP + 10 μ M diC₈-PIP₂ (*solid red trace*), and cGMP + 10 μ M diC₈-PIP₂ (*solid green trace*). *B*, *D*, and *F*, normalized *G-V* relationships for each mutant. All currents were measured from tail currents at -40 mV and normalized (see "Experimental Procedures"). Data in the absence of PIP₂ are shown as *open circles*, and those in the presence of PIP₂ are shown as *closed circles* (see legend in *B*). *Solid and dotted curves* represent fits to the data of the Boltzmann equation (see "Experimental Procedures"). *nn*, no nucleotide; *cA*, cAMP; *cG*, cGMP.

different apparent affinities and that the inhibitory effects are disrupted by the R478C mutation.

DISCUSSION

In this work, we found that PIP₂ had two different and separable effects on SpIH channels. First, as reported previously for mammalian HCN channels (19, 20, 25), PIP₂ potentiated SpIH by causing a depolarizing shift in voltage-dependent activation. Second, PIP₂ also inhibited SpIH, causing a decrease in saturating cGMP-activated currents at maximum hyperpolarizing voltages. For SpIH channels, the inhibition was appreciable only with cGMP and not with cAMP because cGMP is a partial agonist and does not maximally open SpIH channels even at

saturating concentrations. As a result of these two different actions of PIP₂, there is a characteristic crossover of the *G-V* relationships, with PIP₂ causing potentiation at depolarized voltages and inhibition at hyperpolarized voltages.

The PIP₂-induced potentiation was localized to the transmembrane region of the channel containing the pore and voltage-sensing domains because PIP₂ produced shifts in the voltage dependence of SpIH_{ΔC} and SpIH_{ΔNC}. A depolarizing shift in voltage dependence could result from a mechanism in which PIP₂ stabilized either 1) the open state of the pore (relative to the closed state) or 2) the activated (down) state of the voltage sensor (relative to the resting state). These mechanisms can be distinguished based on the effects of PIP₂ on the C-terminal deletion mutants at large hyperpolarizing voltages, where presumably all of the voltage sensors are activated. A stabilization of the open state of the pore might be expected to increase the current even after all the voltage sensors are activated (assuming that the open probability is not already near one). As shown in Fig. 4G, PIP₂ caused a small but significant increase in the cGMP-activated current at hyperpolarized voltages in the deletion mutants, suggesting that the potentiating effect of PIP₂ cannot simply be just on the movement of the voltage sensor. However, if all of the potentiating and inhibitory effects of PIP₂ were acting on the pore in wild-type channels, we would not observe the crossover of the *G-V* curves, which is characteristic of the effects of PIP₂ on wild-type SpIH channels. For these reasons, we favor the idea that PIP₂-induced potentiation of voltage-dependent activation arises in part from a stabilization of the activated state of the voltage sensor. Such stabilization could result from a generalized effect of PIP₂ on the potential




FIGURE 7. Change in free energy of opening caused by PIP₂ modulation of cGMP-modulated SpIH and mutant channels. The bar graph represents mean ΔΔG values ± S.E. (see “Experimental Procedures”). Data sample sizes are shown inside boxes.




FIGURE 8. Dose-response relationship of PIP₂ and PIP in SpIH and K478C mutant channels. *A*, representative SpIH currents measured during a –120-mV test pulse in the presence of 1 mM cGMP (black trace) and increasing concentrations of diC₈-PIP₂ (100 μM = red trace). *B*, representative K478C currents measured during a –120-mV test pulse in the presence of 1 mM cGMP (black trace) and increasing concentrations of diC₈-PIP₂ (100 μM = red trace). *C* and *D*, data from three patches were averaged and plotted as a function of PIP₂ or PIP concentration, respectively. Data were fit with the Hill equation (see “Experimental Procedures”). For SpIH, $I_{PIP_2}/I_{cGMP, No PIP_2} = 55\%$, $K_{1/2, PIP_2} = 3.6 \mu M$, $I_{PIP}/I_{cGMP, No PIP} = 49\%$, and $K_{1/2, PIP} = 13.6 \mu M$.

felt by the voltage sensor (such as a surface charge effect). Alternatively, it could result from a specific electrostatic interaction between the negatively charged PIP₂ and positively charged residues in the activated (down) state of the voltage sensor.

The PIP₂-induced inhibition was localized to the C-terminal region of the channel containing the C-linker and CNBD. Previously, it was proposed that the apo-state of the C-terminal region in HCN channels produces an autoinhibition on channel opening and that the binding of cyclic nucleotide relieves this autoinhibition (24). Consistent with this mechanism, we and others have shown that deletion of the C-terminal region in SpIH channels removes the autoinhibition seen in wild-type SpIH in the absence of cyclic nucleotide (Fig. 2) (13, 24). These results suggest that the mechanism for PIP₂-induced inhibition might be to stabilize the autoinhibitory state of the C-terminal region. The partial agonist cGMP is therefore less able to promote opening in the presence of PIP₂, causing a reduction in current at strong hyperpolarized voltages. However, the full agonist cAMP contributes a greater energy to channel opening and can overcome the inhibition by PIP₂.

A mechanism for autoinhibition has been proposed to involve the C-linker domain (2, 24, 26, 27). The C-linker domain has extensive intersubunit interactions, primarily involving interactions between the A' and B' helices of one subunit and the C' and D' helices of a neighboring subunit. These helices form a gating ring at the intracellular entrance to the pore that may restrict movement of the S6 region and channel opening. We have shown that mutating Arg-478 and Lys-482, positively charged residues on the A' helix adjacent to the membrane, disrupts PIP₂-induced inhibition of SpIH. Interestingly, Arg-478 is not conserved among HCN channels, possibly explaining why no consistent inhibition was seen for mammalian HCN2 (see supplemental Fig. S2 in Ref. 19). Therefore, an electrostatic interaction between Arg-478 and Lys-482 with PIP₂ in the inner leaflet of the membrane may help stabilize the gating ring, producing autoinhibition.

PIP₂ has been shown to regulate many other plasma membrane ion channels and transporters. The list includes inwardly rectifying K⁺ (Kir) channels, KCNQ channels, transient receptor potential channels, voltage-gated calcium channels, epithelial sodium channels, two-P domain potassium channels (K2p), and ion transporters such as the Na⁺-Ca²⁺ exchanger (28, 29). In general, these proteins are activated by PIP₂ or require PIP₂ to function (27). Interestingly, PIP₂ does not activate cyclic nucleotide-gated (CNG) channels. Instead, CNG channels, particularly heteromeric channels formed from CNGB1 and CNGB1 subunits, are inhibited by PIP₂ (30). CNG channels are members of the same cyclic nucleotide-regulated family of channels as HCN channels and contain a C-linker and CNBD structurally similar to the HCN C-terminal region (2, 26, 27). The A' helix of the CNGB subunit contains a positively charged residue at a site equivalent to Arg-478, and the A' helix of the CNGB subunit contains a number of positively charged residues at other sites (Fig. 5A). As in SpIH, PIP₂ has a dual effect on HERG channels, another member of the cyclic nucleotide-regulated family of channels. Application of PIP₂ to HERG channels shifts the voltage dependence of activation to more negative potentials while it also decreases the rate of inactivation

(31). It remains to be determined whether the molecular mechanism for PIP₂ regulation is similar between HCN, CNG, and HERG channels.

Acknowledgments—We are grateful to Kevin Black, Shellee Cunningham, Gay Sheridan, and Stacey Simmons for technical assistance. We thank Drs. Bjoern Falkenburger and Michael Puljung for comments on this manuscript and all members of our local lipid discussion group for helpful suggestions.

REFERENCES

- Biel, M., Wahl-Schott, C., Michalakis, S., and Zong, X. (2009) *Physiol. Rev.* **89**, 847–885
- Craven, K. B., and Zagotta, W. N. (2006) *Annu. Rev. Physiol.* **68**, 375–401
- DiFrancesco, D. (2006) *Prog. Biophys. Mol. Biol.* **90**, 13–25
- Gauss, R., Seifert, R., and Kaupp, U. B. (1998) *Nature* **393**, 583–587
- Ludwig, A., Zong, X., Hofmann, F., and Biel, M. (1999) *Cell Physiol. Biochem.* **9**, 179–186
- Robinson, R. B., and Siegelbaum, S. A. (2003) *Annu. Rev. Physiol.* **65**, 453–480
- Santoro, B., and Tibbs, G. R. (1999) *Ann. N.Y. Acad. Sci.* **868**, 741–764
- Wahl-Schott, C., and Biel, M. (2009) *Cell. Mol. Life Sci.* **66**, 470–494
- Ludwig, A., Zong, X., Jeglitsch, M., Hofmann, F., and Biel, M. (1998) *Nature* **393**, 587–591
- Santoro, B., Grant, S. G., Bartsch, D., and Kandel, E. R. (1997) *Proc. Natl. Acad. Sci. U.S.A.* **94**, 14815–14820
- Santoro, B., Liu, D. T., Yao, H., Bartsch, D., Kandel, E. R., Siegelbaum, S. A., and Tibbs, G. R. (1998) *Cell* **93**, 717–729
- Männikkö, R., Elinder, F., and Larsson, H. P. (2002) *Nature* **419**, 837–841
- Vemana, S., Pandey, S., and Larsson, H. P. (2004) *J. Gen. Physiol.* **123**, 21–32
- Viscomi, C., Altomare, C., Bucchi, A., Camatini, E., Baruscotti, M., Moroni, A., and DiFrancesco, D. (2001) *J. Biol. Chem.* **276**, 29930–29934
- Zagotta, W. N., Olivier, N. B., Black, K. D., Young, E. C., Olson, R., and Gouaux, E. (2003) *Nature* **425**, 200–205
- Flynn, G. E., Black, K. D., Islas, L. D., Sankaran, B., and Zagotta, W. N. (2007) *Structure* **15**, 671–682
- Kornev, A. P., Taylor, S. S., and Ten Eyck, L. F. (2008) *PLoS Comput. Biol.* **4**, e1000056
- Berman, H. M., Ten Eyck, L. F., Goodsell, D. S., Haste, N. M., Kornev, A., and Taylor, S. S. (2005) *Proc. Natl. Acad. Sci. U.S.A.* **102**, 45–50
- Pian, P., Bucchi, A., Robinson, R. B., and Siegelbaum, S. A. (2006) *J. Gen. Physiol.* **128**, 593–604
- Zolles, G., Klöcker, N., Wenzel, D., Weisser-Thomas, J., Fleischmann, B. K., Roeper, J., and Fakler, B. (2006) *Neuron* **52**, 1027–1036
- Zagotta, W. N., Hoshi, T., and Aldrich, R. W. (1989) *Proc. Natl. Acad. Sci. U.S.A.* **86**, 7243–7247
- Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J. (1981) *Pflugers Arch.* **391**, 85–100
- Shin, K. S., Maertens, C., Proenza, C., Rothberg, B. S., and Yellen, G. (2004) *Neuron* **41**, 737–744
- Wainger, B. J., DeGennaro, M., Santoro, B., Siegelbaum, S. A., and Tibbs, G. R. (2001) *Nature* **411**, 805–810
- Pian, P., Bucchi, A., Decostanzo, A., Robinson, R. B., and Siegelbaum, S. A. (2007) *Pflugers Arch.* **455**, 125–145
- Craven, K. B., Olivier, N. B., and Zagotta, W. N. (2008) *J. Biol. Chem.* **283**, 14728–14738
- Craven, K. B., and Zagotta, W. N. (2004) *J. Gen. Physiol.* **124**, 663–677
- Suh, B. C., and Hille, B. (2005) *Curr. Opin. Neurobiol.* **15**, 370–378
- Suh, B. C., and Hille, B. (2008) *Annu. Rev. Biophys.* **37**, 175–195
- Womack, K. B., Gordon, S. E., He, F., Wensel, T. G., Lu, C. C., and Hilgemann, D. W. (2000) *J. Neurosci.* **20**, 2792–2799
- Bian, J. S., and McDonald, T. V. (2007) *Pflugers Arch.* **455**, 105–113
- Long, S. B., Campbell, E. B., and Mackinnon, R. (2005) *Science* **309**, 897–903